MG-4101

N/A

Report date: 2025/04/30 20:00:42

Base Information

Drug NameMG-4101
Drug Alias NameAllogeneic NK cellsMG-4101
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionImmunostimulantsCell replacements
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGC Biopharma CorpSeoul National University Hospital - Abu DhabiSamsung Medical Center +[4] 
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSamsung Medical CenterGC Biopharma CorpGC Cell Corp +[4] 
Active IndicationsN/A
Inactive IndicationsSolid tumoursCarcinoma, HepatocellularLymphoma, Non-Hodgkin +[5] 

Other Information

ATC CodeN/A
Related LinksN/A